Drug intelligence / Profile preview

lutetium Lu 177 dihydroxybenzylidene iminodiacetic acid

Development stage: Preclinical
Lead developer: Bhabha Atomic Research Centre
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Lutetium Lu 177 dihydroxybenzylidene iminodiacetic acid (177Lu-HBIDA) is an experimental therapeutic radiopharmaceutical investigated primarily for the palliation of bone pain in patients with skeletal metastases. The agent consists of the beta-emitting radioisotope lutetium-177 complexed with the Schiff base ligand N-(2,4-dihydroxybenzylidene)iminodiacetic acid (HBIDA). HBIDA serves as a bone-seeking vector, exhibiting high affinity for hydroxyapatite, the primary mineral component of bone. Upon intravenous administration, the complex localizes to areas of active bone remodeling and osteoblastic activity, common in metastatic bone disease. The localized decay of lutetium-177 releases beta particles that deliver targeted cytotoxic radiation to tumor cells and nerve endings within the bone matrix, thereby reducing pain and potentially inhibiting tumor growth. Research on this compound has been notably conducted by the Bhabha Atomic Research Centre (BARC) in India.

Other names: lutetium (177Lu) HBIDA177Lu-labeled N-(2,4-dihydroxybenzylidene)iminodiacetic acidlutetium-177 dihydroxybenzylidene iminodiacetic acidlutetium177 dihydroxybenzylidene iminodiacetic acidlutetium 177 dihydroxybenzylidene iminodiacetic acid

Targets

DNA

Beyond the preview

Go deeper on lutetium Lu 177 dihydroxybenzylidene iminodiacetic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lutetium Lu 177 dihydroxybenzylidene iminodiacetic acid.

Explore the full profile